Volume : 11, Issue : 02, February – 2024

Title:

STABILITY INDICATION RP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR THE ESTIMATION OF BEXAGLIFLOZIN IN MARKETED FORMULATION

Authors :

Sandeep Kumar Tiwari*, Deepak Kumar Basedia, Vivek Thakur, B. K. Dubey

Abstract :

This study focuses on the development and validation of a stability-indicating reverse-phase high-performance liquid chromatography (RP-HPLC) method for the accurate estimation of Bexagliflozin in a marketed formulation. Bexagliflozin, a novel sodium-glucose cotransporter-2 (SGLT-2) inhibitor, is widely used for the management of type 2 diabetes mellitus. The proposed RP-HPLC method demonstrates stability indicating attributes, enabling the assessment of drug integrity in the presence of potential degradants. The validation parameters, including specificity, linearity, precision, accuracy, robustness, and system suitability, were systematically evaluated. Additionally, the method was successfully applied to quantify Bexagliflozin in a commercially available formulation, providing a reliable tool for routine quality control analysis. The developed method offers a valuable contribution to the pharmaceutical analytical toolbox, ensuring the accurate determination of Bexagliflozin in the presence of potential degradation products.
Key Words: Bexagliflozin, stability indicating, RP-HPLC, method development, validation, marketed formulation,

Cite This Article:

Please cite this article in press Deepak Kumar Basedia et al., Stability Indication Rp-Hplc Method Development And Validation For The Estimation Of Bexagliflozin In Marketed Formulation, Indo Am. J. P. Sci, 2024; 11 (02).

Number of Downloads : 10

References:

1. Inzucchi, S. E., et al. (2015). SGLT-2 Inhibitors and Cardiovascular Risk: Proposed Pathways and Review of Ongoing Outcome Trials. Diabetes & Vascular Disease Research, 12(2), 90–100.
2. Zinman, B., et al. (2015). Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. The New England Journal of Medicine, 373(22), 2117–2128.
3. FDA. (2013). Guidance for Industry: Q1A(R2) Stability Testing of New Drug Substances and Products. Retrieved from https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q1ar2-stability-testing-new-drug-substances-and-products
4. ICH. (2003). Stability Testing of New Drug Substances and Products (Q1A(R2)). Retrieved from https://database.ich.org/sites/default/files/Q1A_R2__Guideline.pdf
5. K. Swaroopa Rani, B. Ramya Kuber, Analytical Quality By Design Methodology For Bexagliflozin Assessment In Formulation In The Presence Of Degradants Using Rp-Hplc, Eur. Chem. Bull. 2023, 12(Regular Issue 07), 4320-4-4335